In September 2023, Heidelberg University Medical School in Germany released a groundbreaking study on Aescin, a natural active compound extracted from horse chestnut seeds. The research revealed that Aescin has significant anti-inflammatory, anti-edema, and circulation-improving properties, providing new scientific evidence for its application in medicine and health.
The research team conducted clinical trials on hundreds of patients with chronic venous insufficiency (CVI) and edema, finding that the use of Aescin-based medication reduced swelling symptoms by an average of 40% and significantly lowered inflammation markers, with no notable side effects. Additionally, Aescin was shown to enhance vascular elasticity and improve microcirculation, suggesting potential benefits for treating varicose veins and post-surgical edema.
As a traditional herbal ingredient, Aescin has been widely used in Europe to treat venous disorders and traumatic swelling. In recent years, its applications have expanded to skincare and sports recovery. For example, an international brand’s Aescin-based soothing gel has gained popularity for its effectiveness in reducing post-exercise swelling and muscle fatigue.
Industry experts predict that as demand for natural medicines and health products grows, the market size for Aescin will continue to expand. By 2025, the global Aescin market is expected to exceed $300 million, becoming a significant growth driver in the pharmaceutical and health industries.
The advancements in Aescin research not only provide scientific validation for the modern application of traditional herbal ingredients but also offer consumers safer and more effective health solutions. With advancing research and growing market demand, Aescin is poised to play an even greater role in medicine and health.
Note: The content is for reference only. Please carefully verify and discern the information.
